Why the Deal for AveXis Is a Powerful Vote for Replacement Gene … – Barron’s
Barron’s |
Why the Deal for AveXis Is a Powerful Vote for Replacement Gene …
Barron’s Novartis's $8.7 billion deal to buy AveXis, one of the leaders in replacement gene therapy, amounts to a strong endorsement of the developing biotechnology. It also looks bullish for Regenxbio, which makes the viral delivery mechanism for AveXis's … How a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech Analyst: AveXis M&A Could Support Interest In Regenxbio Zacks Premium Investment Service – Zacks.com |
